Black Diamond Therapeutics/$BDTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Black Diamond Therapeutics
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Ticker
$BDTX
Sector
Primary listing
Employees
24
Headquarters
BDTX Metrics
BasicAdvanced
$157M
11.03
$0.25
2.88
-
Price and volume
Market cap
$157M
Beta
2.88
52-week high
$6.75
52-week low
$1.20
Average daily volume
970K
Financial strength
Current ratio
8.731
Quick ratio
8.499
Long term debt to equity
12.797
Total debt to equity
15.649
Profitability
EBITDA (TTM)
7.994
Gross margin (TTM)
100.00%
Net profit margin (TTM)
20.63%
Operating margin (TTM)
10.93%
Revenue per employee (TTM)
$2,920,000
Management effectiveness
Return on assets (TTM)
3.02%
Return on equity (TTM)
11.85%
Valuation
Price to earnings (TTM)
11.025
Price to revenue (TTM)
2.234
Price to book
1.18
Price to tangible book (TTM)
1.18
Price to free cash flow (TTM)
8.749
Free cash flow yield (TTM)
11.43%
Free cash flow per share (TTM)
0.315
Growth
Earnings per share change (TTM)
-116.30%
3-year earnings per share growth (CAGR)
-56.38%
What the Analysts think about BDTX
Analyst ratings (Buy, Hold, Sell) for Black Diamond Therapeutics stock.
BDTX Financial Performance
Revenues and expenses
BDTX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Black Diamond Therapeutics stock?
Black Diamond Therapeutics (BDTX) has a market cap of $157M as of August 18, 2025.
What is the P/E ratio for Black Diamond Therapeutics stock?
The price to earnings (P/E) ratio for Black Diamond Therapeutics (BDTX) stock is 11.03 as of August 18, 2025.
Does Black Diamond Therapeutics stock pay dividends?
No, Black Diamond Therapeutics (BDTX) stock does not pay dividends to its shareholders as of August 18, 2025.
When is the next Black Diamond Therapeutics dividend payment date?
Black Diamond Therapeutics (BDTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Black Diamond Therapeutics?
Black Diamond Therapeutics (BDTX) has a beta rating of 2.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.